VXRT logo

VXRT
Vaxart Inc

74,714
Mkt Cap
$170.85M
Volume
494,037.00
52W High
$0.8449
52W Low
$0.2606
PE Ratio
12.30
VXRT Fundamentals
Price
$0.7295
Prev Close
$0.71
Open
$0.648
50D MA
$0.6631
Beta
1.37
Avg. Volume
559,565.09
EPS (Annual)
$0.0709
P/B
2.00
Rev/Employee
$3.21M
$29.03
Loading...
Loading...
News
all
press releases
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +0.98% and -91.09%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
More News
News Placeholder
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates
CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.66% and -94.70%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates
VAXART (VXRT) delivered earnings and revenue surprises of +22.22% and +1,206.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8mo ago
News Placeholder
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -13.68% and -5.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8mo ago
News Placeholder
The Beauty Health Company (SKIN) Surpasses Q2 Earnings and Revenue Estimates
Beauty Health (SKIN) delivered earnings and revenue surprises of +150.00% and +4.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8mo ago
News Placeholder
Select Medical (SEM) Surpasses Q2 Earnings and Revenue Estimates
Select Medical (SEM) delivered earnings and revenue surprises of +14.29% and +1.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9mo ago
News Placeholder
Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching
Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.
Stocktwits·1y ago
<
...
1
>

Latest VXRT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.